| Title | HE3286: A Novel Synthetic Steroid as an Oral Treatment for Autoimmune Disease. | | Author(s) | Ahlem C, Auci D, Mangano K, Reading C, Frincke J, Stickney D, Nicoletti F | | Institution | Hollis-Eden Pharmaceuticals, San Diego, California, USA. | | Source | Ann N Y Acad Sci 2009 Sep.:781-90. | | Abstract | HE3286 (17alpha-ethynyl-5-androstene-3beta, 7beta, 17beta-triol) is a synthetic derivative of a natural anti-inflammatory steroid, beta-AET (5-androstene-3beta, 7beta, 17beta-triol). HE3286 is orally bioavailable and treats established disease in models of ulcerative colitis, collagen-induced arthritis, and collagen antibody-induced arthritis, reducing clinical signs of disease and proinflammatory signals, including IL-6 and matrix metallopeptidase 3. HE3286 modulates nuclear factor kappaB through an unknown mechanism but does not interact with any of the steroid-binding nuclear hormone receptors and is not immune suppressive. HE3286 was safe and well tolerated in phase I studies and is under evaluation in multicenter phase I/II clinical trials for ulcerative colitis and arthritis. HE3286 may provide a new treatment option for patients with inflammatory and autoimmune diseases. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19758229 |
|
